EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudieOpen Access · CC BY 4.0

A Systematic Review and Meta‐Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma

Jiahua Hu, Lisha Pan, Hong Kong, Jiaqi Lou iD

Journal of Cosmetic Dermatology · 2026-02 · 25 (2)

DOI: 10.1111/jocd.70750 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 17.02.2026. Verfasst von Jiahua Hu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Huzhou Maternity & Child Health Care Hospital, Huzhou City, China. Hauptthemen laut MEDLINE: Atenolol, Hemangioma, Propranolol, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Fund of Zhejiang Provincial Education Department, Zhejiang Province Health Industry Science and Technology Plan 2025, Ningbo Research Center for Traditional Chinese Medicine (TCM) Culture, a Key Cultural Research Base of Ningbo City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to systematically evaluate and compare the efficacy and safety of propranolol versus atenolol, corticosteroids, timolol, and other therapies in the treatment of infantile hemangioma (IH) through a meta‐analysis, thereby providing evidence‐based guidance for clinical practice.

Methods

A comprehensive literature search was conducted across PubMed, Cochrane Library, EMBASE, Web of Science, CNKI, and Wanfang databases from inception to December 2025. The protocol was prospectively registered with PROSPERO (CRD420261294316). Randomized controlled trials (RCTs) or clinical controlled trials (CCTs) comparing oral propranolol with other active drugs in IH patients aged ≤ 12 years were included. Primary outcomes were overall response rate (≥ 50% reduction), complete remission rate, and incidence of adverse events. Two reviewers independently performed study selection, data extraction, and quality assessment using the Cochrane RoB 2.0 tool and Newcastle‐Ottawa Scale. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using R software. Heterogeneity was assessed using the I 2 statistic.

Results

Eight studies involving 900 patients (propranolol: 464; control: 436) were included. Meta‐analysis revealed no statistically significant difference in overall response rate between propranolol and control groups (pooled OR = 1.29, 95% CI: 0.80–2.09, p = 0.30). However, propranolol demonstrated a significantly higher complete remission rate (OR = 1.35, 95% CI: 1.01–1.82, p = 0.045). Subgroup analyses by control drug type (atenolol, corticosteroids, timolol, combination therapy) showed no significant differences in efficacy (all p > 0.05). Safety analysis indicated no significant difference in adverse event incidence between groups (OR = 0.76, 95% CI: 0.38–1.55, p = 0.45), albeit with moderate heterogeneity ( I 2 = 56%). Heterogeneity was low for efficacy outcomes ( I 2 = 0%). Funnel plot symmetry and a non‐significant Egger's test suggested a low risk of publication bias.

Conclusion

Propranolol offers a statistically significant advantage in achieving complete remission of infantile hemangioma compared to other active agents, while maintaining comparable overall response rates and a similar overall safety profile. These findings support propranolol as a first‐line therapy when complete lesion resolution is the primary goal. Atenolol represents an effective alternative, particularly for patients with specific tolerability concerns, underscoring the need for individualized treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtenololHemangiomaPropranololSkin NeoplasmsHumansInfantAdrenal Cortex HormonesHemangioma, CapillaryRandomized Controlled Trials as TopicRemission InductionTimololTreatment Outcome

Stichwörter der Autor:innen

atenololefficacyinfantile hemangiomameta‐analysispropranololsafetysystematic review

Substanzen

Adrenal Cortex HormonesAtenololPropranololTimolol

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Huzhou Maternity & Child Health Care Hospital, Huzhou City, China.
  • Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou City, China.
  • Ningbo College of Health Sciences, Ningbo, China.
  • Burn Department, Ningbo No. 2 Hospital, Wenzhou Medical University, Ningbo, China.

ORCID-Profile: Jiaqi Lou

Förderung

  • Scientific Research Fund of Zhejiang Provincial Education Department
  • Zhejiang Province Health Industry Science and Technology Plan 2025
  • Ningbo Research Center for Traditional Chinese Medicine (TCM) Culture, a Key Cultural Research Base of Ningbo City
  • Natural Science Foundation of Ningbo Municipality

Zitieren

APA

Hu, J., Pan, L., Kong, H., & Lou, J. (2026). A Systematic Review and Meta‐Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma. Journal of Cosmetic Dermatology, 25(2). https://doi.org/10.1111/jocd.70750

Vancouver

Hu J, Pan L, Kong H, Lou J. A Systematic Review and Meta‐Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma. Journal of Cosmetic Dermatology. 2026;25(2). doi:10.1111/jocd.70750

BibTeX
@article{Hu2026,
  author = {Hu, Jiahua and Pan, Lisha and Kong, Hong and Lou, Jiaqi},
  title = {A Systematic Review and Meta‐Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma},
  journal = {Journal of Cosmetic Dermatology},
  year = {2026},
  volume = {25},
  number = {2},
  doi = {10.1111/jocd.70750}
}
Kostenlos starten →